The lab will allow for faster cancer biopsy results, which previously took weeks thanks to shipping times.
“We are now able to test for far more genetic mutations, allowing us to target therapies for patients’ cancers,” Charles Myers, MD, a pathologist and director of Norton Cancer Institute Genomics Lab, said in the release.
The lab can test for mutations in more than 50 genes; previously, Norton’s facilities could test for mutations in only three.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
